2018
Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients
Brook RD, Kaciroti N, Bakris G, Dahlöf B, Pitt B, Velazquez E, Weber M, Zappe DH, Hau T, Jamerson KA. Prior Medications and the Cardiovascular Benefits From Combination Angiotensin‐Converting Enzyme Inhibition Plus Calcium Channel Blockade Among High‐Risk Hypertensive Patients. Journal Of The American Heart Association 2018, 7: e006940. PMID: 29301757, PMCID: PMC5778960, DOI: 10.1161/jaha.117.006940.Peer-Reviewed Original ResearchMeSH KeywordsAgedAmlodipineAngiotensin-Converting Enzyme InhibitorsAntihypertensive AgentsBenzazepinesBlood PressureCalcium Channel BlockersCause of DeathDrug Therapy, CombinationFemaleHumansHydrochlorothiazideHypertensionMaleMiddle AgedRandomized Controlled Trials as TopicRisk AssessmentRisk FactorsSodium Chloride Symporter InhibitorsTime FactorsTreatment OutcomeConceptsHigh-risk hypertensive patientsCardiovascular risk reductionHypertensive patientsAntihypertensive regimenCombination therapyBlood pressure control statusGreater cardiovascular risk reductionRenin-angiotensin system blockadeAngiotensin-converting enzyme inhibitorPrimary composite eventsPrior antihypertensive therapyPrimary composite outcomeCalcium channel blockadeLipid-lowering medicationsPrior medication useCalcium channel blockersRisk reductionACCOMPLISH trialAntihypertensive therapySystem blockadeCardiovascular benefitsCombination regimenComposite outcomeDrug regimensMedication use
2008
Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients
Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ. Benazepril plus Amlodipine or Hydrochlorothiazide for Hypertension in High-Risk Patients. New England Journal Of Medicine 2008, 359: 2417-2428. PMID: 19052124, DOI: 10.1056/nejmoa0806182.Peer-Reviewed Original ResearchConceptsNonfatal myocardial infarctionCardiovascular eventsNonfatal strokeCardiovascular causesMyocardial infarctionHigh riskEnd pointDihydropyridine calcium channel blockerCurrent U.S. guidelinesComposite of deathDouble-blind trialPrimary end pointPrimary outcome eventSecondary end pointsHigh-risk patientsAbsolute risk reductionRelative risk reductionCalcium channel blockersCombination drug therapySudden cardiac arrestRisk reductionCoronary revascularizationStudy drugAdverse eventsBaseline characteristics
2004
Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial
Jamerson K, Bakris G, Wun C, Dahlöf B, Lefkowitz M, Manfreda S, Pitt B, Velazquez E, Weber M. Rationale and design of the avoiding cardiovascular events through combination therapy in patients living with systolic hypertension (ACCOMPLISH) trial. American Journal Of Hypertension 2004, 17: 793-801. PMID: 15363822, DOI: 10.1016/j.amjhyper.2004.05.004.Peer-Reviewed Original ResearchConceptsSystolic Hypertension (ACCOMPLISH) trialCardiovascular eventsBlood pressureHypertension trialsCombination therapyOptimal BP controlPrimary study endpointCalcium channel blockersClass of drugsBP controlCardiovascular outcomesHypertensive patientsPrimary endpointCardiovascular mortalityStudy endpointACE inhibitorsHypertension managementFirst patientClinical eventsAntihypertensive combinationsRisk factorsSuch therapyRecent guidelinesDrug classesVasculoprotective properties